Citizens JMP analyst Jason Butler reiterated a Market Outperform rating on Rapport Therapeutics (NASDAQ: RAPP).The analyst commented, “Phase 2a results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE